Blog

  • How SAP’s Q3 Cloud Surge and Major Contract Wins (XTRA:SAP) Have Changed Its Investment Story

    How SAP’s Q3 Cloud Surge and Major Contract Wins (XTRA:SAP) Have Changed Its Investment Story

    • SAP SE reported strong third quarter 2025 results, with cloud revenue rising 27% and total revenue reaching €9.08 billion, as management highlighted accelerating adoption of its Business Suite and AI-driven cloud offerings.

    • Significant public sector wins, including a €1 billion contract with the U.S. Army and new AI-powered solutions, contributed to upgraded full-year guidance and reinforced SAP’s position as a leader in enterprise cloud transformation.

    • We’ll examine how SAP’s robust Q3 cloud revenue growth and major contract wins could influence its investment narrative going forward.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    To be a shareholder in SAP, one needs to believe in its transition to a cloud-first enterprise software model and sustained growth in cloud and AI-driven services. The latest Q3 results, with 27% cloud revenue growth and a €1 billion U.S. Army contract, provide positive momentum for short-term catalysts like cloud bookings and reinforce the leadership narrative. However, the company’s confirmation that full-year cloud revenue will land at the lower end of guidance highlights persistent risks from elongated public sector sales cycles.

    Among recent announcements, SAP’s completion of the SmartRecruiters acquisition supports cloud expansion efforts and addresses one of its biggest revenue and margin catalysts, broadening the portfolio and increasing the value of recurring cloud contracts. This acquisition not only enhances SAP’s HR cloud functionality but also adds further scale to its subscription-based offering, reinforcing cloud-led revenue catalysts in the wake of strong Q3 figures.

    Yet, despite these growth signs, investors should be aware that pressure on sales cycles in sectors like the U.S. public sector could still…

    Read the full narrative on SAP (it’s free!)

    SAP’s outlook envisions €50.9 billion in revenue and €10.3 billion in earnings by 2028. This is based on analysts’ expectations of 12.3% annual revenue growth and a €3.8 billion increase in earnings from the current €6.5 billion.

    Uncover how SAP’s forecasts yield a €287.60 fair value, a 23% upside to its current price.

    XTRA:SAP Community Fair Values as at Oct 2025

    Simply Wall St Community members provided 20 fair value estimates for SAP, ranging from €234.97 to €345 per share. While many see substantial upside, risks remain around the pace of cloud revenue growth and the impact of protracted enterprise purchasing cycles on future results, so you may want to consider other views before making a decision.

    Explore 20 other fair value estimates on SAP – why the stock might be worth just €234.97!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    • A great starting point for your SAP research is our analysis highlighting 4 key rewards that could impact your investment decision.

    • Our free SAP research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate SAP’s overall financial health at a glance.

    Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SAP.DE.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Revisiting Valuation After Strong Shareholder Returns and Persistent Growth Trends

    Revisiting Valuation After Strong Shareholder Returns and Persistent Growth Trends

    Ajinomoto (TSE:2802) shares have drawn fresh attention as investors revisit the company’s performance this month. While there has not been any single headline event, several market watchers are observing how its ongoing growth trends might influence future returns.

    See our latest analysis for Ajinomoto.

    Ajinomoto’s share price momentum has stayed positive, climbing nearly 33% year-to-date and maintaining a robust uptrend. With a striking 1-year total shareholder return of 51% and five-year returns above 330%, long-term investors have been rewarded as optimism builds around the company’s growth strategy.

    If Ajinomoto’s steady climb has you thinking bigger, now is the perfect moment to explore fast growing stocks with high insider ownership.

    But with shares hovering near their price targets after years of strong gains, investors may wonder if Ajinomoto is still trading below its true value or if the market has already factored in all the expected growth ahead.

    Ajinomoto’s last close at ¥4,231 sits just below the narrative fair value estimate of ¥4,377. This marginal gap amplifies the debate over whether recent innovations and partnerships could unlock further upside, or if current expectations already reflect the company’s full earnings potential.

    “Ongoing investment in R&D and human capital, particularly in Functional Materials and Bio-Pharma Services, is expected to yield differentiated, higher-value products (e.g., specialty amino acids, AI/PC/server-related materials), strengthening competitive moat and gradually improving net margins over the long term.”

    Read the complete narrative.

    Want to know exactly which breakthrough bets and financial projections are shaping this valuation? The “secret sauce” is a bold mix of future margin expansion, ambitious growth forecasts, and the expectation of a premium price tag usually reserved for market innovators. Find out what underpins this bullish vision if you are ready for a deep dive.

    Result: Fair Value of ¥4,377 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent raw material cost inflation and weak demand in certain core markets could quickly derail Ajinomoto’s bullish recovery expectations.

    Find out about the key risks to this Ajinomoto narrative.

    While Ajinomoto looks slightly undervalued from a fair value perspective, its current price reflects a very high price-to-earnings ratio of 52.4 times. This is not just above the Japanese Food industry average of 16.4 times and its closest peers at 17.6 times, but also significantly exceeds the fair ratio of 33.8 times. This signals stretched expectations and higher valuation risk for investors. Is this optimism sustainable, or could it leave the stock vulnerable if growth falls short?

    See what the numbers say about this price — find out in our valuation breakdown.

    TSE:2802 PE Ratio as at Oct 2025

    If you want to challenge the consensus or dig through the numbers yourself, you can build a personalized view in just a few minutes. Do it your way.

    A great starting point for your Ajinomoto research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.

    Serious about building a standout portfolio? Skip the guesswork and let powerful data point you toward tomorrow’s winners. Don’t settle for ordinary opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include 2802.T.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Assessing Valuation After Phase 3 Trial Failure and Major Business Overhaul

    Assessing Valuation After Phase 3 Trial Failure and Major Business Overhaul

    Alector (ALEC) recently reported that its experimental therapy latozinemab did not meet the main efficacy goal in a late-stage trial for frontotemporal dementia. As a result, multiple follow-up studies are being discontinued, and the company is reorganizing its operations.

    See our latest analysis for Alector.

    It has been a dramatic stretch for Alector’s stock. Following news of the Phase 3 trial setback and sweeping operational changes, the one-week share price return plunged by over 50%, and the one-month figure sits at -52.5%. Even before this, momentum had been fading; the 1-year total shareholder return is down 68%, highlighting ongoing challenges for both short- and long-term holders despite a small rebound in the most recent session.

    If unexpected biotech moves get you thinking about where the next big story could emerge, this is a great moment to discover fast growing stocks with high insider ownership

    With steep losses already reflected in Alector’s share price, the key question is whether the market has overreacted and created a bargain, or if the valuation now fairly accounts for fading prospects and future uncertainty.

    Alector’s widely followed narrative suggests a fair value notably above the latest $1.50 close, which hints at market pessimism that may be overdone. The most influential argument highlights the importance of pivotal data still to come and the company’s unique approach, setting up a fascinating debate over potential upside versus recent setbacks.

    Alector’s proprietary expertise and platform for blood-brain barrier delivery of large therapeutic molecules addresses a critical bottleneck in CNS drug development and enables pipeline programs targeting Alzheimer’s, Parkinson’s, and additional neurodegenerative diseases. This lays the groundwork for sustained long-term revenue growth and enhanced gross margins if these programs advance.

    Read the complete narrative.

    What is the secret ingredient inside this valuation? The narrative banks on aggressive revenue acceleration and a total earnings turnaround. Does the fair value truly reflect high expectations for scientific breakthroughs and blockbuster partnerships? Readers with an eye for bold forecasts will want to see the numbers driving this price call.

    Result: Fair Value of $2.20 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, if regulatory hurdles grow or development setbacks persist, confidence in Alector’s ambitious turnaround narrative could quickly begin to unravel.

    Find out about the key risks to this Alector narrative.

    If this story does not match your perspective, or if you would rather investigate the numbers directly, you can craft your own assessment in just a few minutes. Do it your way

    A great starting point for your Alector research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

    Expand your horizons and go beyond the headlines. Thousands of investors are already scouting new opportunities you might be missing right now. Take charge of your investing strategy and gain the edge you deserve by checking out these unique opportunities:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ALEC.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • White dwarf star is still feasting on dead Earth-like planet 3 billion years later

    White dwarf star is still feasting on dead Earth-like planet 3 billion years later

    Astronomers recently peered deep into space and found that an old, faint white dwarf named LSPM J0207+3331, located about 145 light-years away, is still consuming the rocky remains of its former planets. This star, about the size of Earth but…

    Continue Reading

  • Can Schrödinger (SDGR) Sustain Its AI Edge in Drug Discovery as Q3 Results Approach?

    Can Schrödinger (SDGR) Sustain Its AI Edge in Drug Discovery as Q3 Results Approach?

    • Schrödinger announced it will release its third quarter 2025 financial results on November 5, 2025, followed by a live webcast and conference call for investors.

    • The company has attracted increasing industry attention as a pioneer in applying artificial intelligence to accelerate drug discovery and reshape biotechnology innovation.

    • We’ll explore how recognition of Schrödinger’s AI leadership amid growing sector focus may influence its long-term investment outlook.

    Find companies with promising cash flow potential yet trading below their fair value.

    To be a shareholder of Schrödinger, you need to believe the company’s AI-driven software can become essential to drug discovery, leading to scalable, recurring revenues and clinical milestones. The upcoming third quarter 2025 results announcement and investor call, while relevant for short-term sentiment, does not materially change the main near-term catalyst, new clinical data for SGR-1505, nor does it resolve the biggest risk of sluggish new client acquisition amid biotech sector headwinds.

    The most closely related recent announcement is Schrödinger’s update on initial clinical results for SGR-1505, a MALT1 inhibitor, which showed early efficacy and received FDA Fast Track designation this June. This progress in the clinic positions SGR-1505 as a primary driver for milestone payments and licensing, supporting management’s focus on revenue growth from drug discovery and anchoring the short-term investment outlook.

    However, investors should also be mindful that, in contrast to the excitement around new clinical milestones, ongoing challenges in expanding the customer base persist and…

    Read the full narrative on Schrödinger (it’s free!)

    Schrödinger’s narrative projects $396.6 million revenue and $34.8 million earnings by 2028. This requires 18.6% yearly revenue growth and a $216.1 million increase in earnings from the current level of -$181.3 million.

    Uncover how Schrödinger’s forecasts yield a $27.30 fair value, a 21% upside to its current price.

    SDGR Community Fair Values as at Oct 2025

    Six independent valuations from the Simply Wall St Community place fair value for Schrödinger between US$27.00 and US$43.20 per share. While some see upside, many remain focused on the risk that slow new client acquisition could constrain long-term revenue growth and influence market sentiment ahead of earnings; explore the range of outlooks shaping this debate.

    Explore 6 other fair value estimates on Schrödinger – why the stock might be worth as much as 92% more than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SDGR.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • A Fresh Look at Valuation After Sector Jitters Triggered by Texas Instruments Forecast

    A Fresh Look at Valuation After Sector Jitters Triggered by Texas Instruments Forecast

    Shares of Skyworks Solutions (SWKS) slipped 3% after a disappointing outlook from Texas Instruments. This development heightened concerns about a slowing recovery across the broader semiconductor industry and cast a shadow over sector performance.

    See our latest analysis for Skyworks Solutions.

    Against the backdrop of sector-wide jitters sparked by Texas Instruments’ outlook, Skyworks Solutions’ share price has lost ground this month and year-to-date, with a 1-year total shareholder return of -19%. While the company continues to roll out technical advances and earn industry recognition, recent momentum is clearly fading as investors reassess risk across the entire semiconductor space.

    Curious to see which other chipmakers might be showing resilience or fresh growth? You can spot new opportunities with our tech and AI stocks screener using See the full list for free.

    With shares now trading well below their five-year highs and sentiment at a low, the crucial question for investors is whether Skyworks Solutions is an undervalued opportunity or if the market is accurately pricing in future challenges and limited growth ahead.

    Skyworks Solutions’ last close of $74.04 stands slightly above the most-followed narrative’s fair value calculation of $72.47. Analyst consensus believes that near-term improvements may be limited, which sets the stage for ongoing debate around whether today’s market price is justified or too optimistic.

    Accelerated adoption of advanced wireless standards and AI-capable smartphones is increasing the RF content required per device. This positions Skyworks to benefit from higher average selling prices and potential unit volume growth, and may drive revenue and gross margin expansion.

    Read the complete narrative.

    What forecast is powering this valuation? The narrative quietly hinges on a projected turnaround in profit margins, a wave of new revenue sources, and bold expectations for industry cycles. The real surprise is how consensus thinks Skyworks will overcome recent headwinds. Wonder what hidden lever is at the core? Explore the full story to see which future assumptions could send shares in either direction.

    Result: Fair Value of $72.47 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, risks remain, such as Skyworks’ reliance on a single major customer and persistent competition. Either factor could challenge even the most optimistic scenario.

    Find out about the key risks to this Skyworks Solutions narrative.

    While the analyst consensus suggests Skyworks Solutions is fairly valued or slightly overvalued using market multiples, our DCF model tells a different story. The SWS DCF model estimates fair value at $110.36 per share, which is far above today’s price. This hints at a meaningful undervaluation the market could be overlooking. Can this gap persist, or will investors eventually close it?

    Look into how the SWS DCF model arrives at its fair value.

    SWKS Discounted Cash Flow as at Oct 2025

    If you see things differently, or want to bring your own perspective to the numbers, crafting your own narrative takes just a few minutes. Do it your way

    A great starting point for your Skyworks Solutions research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

    Take action now and supercharge your watchlist by targeting untapped markets, growth leaders, or stable income opportunities before the crowd catches on.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SWKS.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Evaluating Whether Shares Are Undervalued After Recent Shift in Market Sentiment

    Evaluating Whether Shares Are Undervalued After Recent Shift in Market Sentiment

    QuidelOrtho (QDEL) has been navigating a challenging market in recent months, facing headwinds that have impacted its share price. Recent performance offers investors reason to revisit the company’s fundamentals as they evaluate longer-term prospects.

    See our latest analysis for QuidelOrtho.

    QuidelOrtho’s 14% share price gain over the past month hints at shifting market sentiment; however, the bigger picture remains challenging given a 1-year total shareholder return of -21% and a steep three-year loss. While momentum has picked up recently, long-term holders are still waiting for a meaningful turnaround.

    If you’re considering what else is out there in healthcare, take this as your cue to discover See the full list for free.

    With shares trading at a hefty discount to analyst price targets, but longer-term returns still deeply negative, investors have to ask whether QuidelOrtho is undervalued at current levels or if the market is already accounting for any future growth potential.

    With QuidelOrtho’s fair value calculation at $40.33 and a last close of $30.51, the narrative suggests there’s significant upside potential if the company meets its projected milestones. Here’s a core insight from the most widely followed narrative driving this view.

    Acquisition of LEX Diagnostics and the planned commercialization of its rapid molecular point-of-care platform addresses the trend toward fast, decentralized testing and is likely to increase recurring revenues and enhance margins as high-value, high-velocity diagnostic solutions become more prevalent.

    Read the complete narrative.

    Curious what numbers could justify this big premium? The full narrative lays out a bold path that includes profitability targets and a future multiple that is out of step with today’s reality. Don’t miss the surprising projections and assumptions that power this price target.

    Result: Fair Value of $40.33 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent declines in COVID-related revenues and challenges from discontinued product lines could undermine near-term gains. These factors may test the company’s turnaround narrative.

    Find out about the key risks to this QuidelOrtho narrative.

    If you see the numbers differently or want to shape your own perspective, you can dive into the data and build your own narrative in just a few minutes. Do it your way

    A great starting point for your QuidelOrtho research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    Smart investors seize opportunities early. Expand your horizons and spot emerging trends by taking action now with these targeted stock picks from Simply Wall Street’s powerful screener:

    • Fuel your search for tomorrow’s leaders with these 27 AI penny stocks. These stocks are shaping innovation in artificial intelligence and redefining what’s possible in tech-driven markets.

    • Unlock potential steady income by evaluating these 17 dividend stocks with yields > 3%. These stocks deliver robust yields above 3%, which may be ideal for building a resilient portfolio.

    • Capitalize on inefficiencies by targeting value with these 880 undervalued stocks based on cash flows. These stocks are uniquely screened for attractive prices based on underlying cash flows.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include QDEL.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Leading firms are falling behind in developing East Asia

    Advances in transport and communication technologies in the 1980s and 1990s allowed the proliferation of global value chains that spurred the East Asian growth miracle (Baldwin 2016, Williamson and O’Rourke 2017).  Recent decades have seen a new wave of disruptive technologies like robots, AI and digital platforms. Yet, this period has coincided with a deceleration in East Asian productivity (‘total factor productivity’) growth.

    While this productivity slowdown has been global, it is far from uniform. In OECD economies, the top-performing firms – often referred to as the ‘global frontier’ – have maintained rapid productivity growth. The overall slowdown in OECD economies comes from a growing gap between these leaders and the rest (Blanchenay et al. 2017, Criscuolo et al. 2017).  What remains less understood is how these dynamics play out in emerging economies.

    Frontier firms in East Asia are falling behind

    Why has this productivity slowdown in East Asia come at a time of rapid technological progress?  To address this question, in De Nicola et al. (2025) we use newly harmonised firm-level data from national statistical agencies across five major East Asian economies.

    First, in East Asia, around three quarters of aggregate productivity growth has been due to increases within existing firms.  Very little is contributed to productivity growth by the reallocation of market share across firms or from firm entry and exit.  In fact, the market share of the national frontier firms – the 10% most productive firms in a sector – is declining.  Resources appear to be trapped in less-productive firms that should shrink or exit, which could enable more-productive firms to scale up.

    Second, productivity growth within the national frontier firms has been slower than among less productive firms. Frontier firms account for a large share of output and employment and around half of all within-firm productivity growth, so their stagnation weighs heavily on overall productivity.

    While slower growth relative to less productive firms may reflect desirable domestic convergence, productivity gaps between East Asia’s frontier firms and the global frontier are widening in digital-intensive sectors — such as electronics, IT services, and pharmaceuticals. Between 2005 and 2015, global frontier firms in digital manufacturing boosted productivity by 76%. In contrast, national frontier firms in Indonesia, Malaysia, the Philippines, and Viet Nam achieved only a 34% increase over the same period (refer to Figure 1).

    One reason for the underperformance of leading firms in East Asia is the uneven adoption of advanced technology. The gap in technology use between firms in East Asia and Pacific (EAP) and the world’s most sophisticated firms has widened, much more so than the gap between the average EAP firms and their global counterparts. The diffusion of accessible technologies like mobile internet is almost universal, whereas big differences persist for sophisticated technologies that drive frontier firm growth.

    Figure 1 The national frontier in EAP countries is falling behind the global frontier, especially in digital sectors

    Note: “National frontier” refers to the 90th percentile of the firm productivity distribution for each country and industry and “global frontier” to the 95th percentile of the firm productivity distribution across high-income economies within an industry.  The distance between the national and global frontier productivity is normalized to 0 in the first year, such that negative numbers reflect the national frontier falling further behind the global frontier relative to the first year, and positive numbers reflect the national frontier catching up with or exceeding the global frontier. Sector “digital intensity” is defined according to Eurostat’s Digital Intensity Index, which classifies high-technology manufacturing and high-knowledge-intensive services as “digital-intensive sectors” and other manufacturing and services sectors as “less-digital-intensive sectors.” CHN = China; IDN = Indonesia; MYS = Malaysia; PHL = Philippines; VNM = Viet Nam.

    Why are the leaders not leading? How can policy help?

    The relative stagnation of East Asia’s top firms may be because they lack adequate competition incentives and the relevant capabilities, such as high-quality skills and infrastructure.

    1 Firms need stronger incentives

    Barriers to competition in both goods and services markets stifle the incentive for the top firms to innovate. Firms that are close to the frontier innovate to stay ahead of their competitors, whereas laggard firms are discouraged and innovate less (Aghion et al. 2021).  For example, Chinese import competition has been found to increase the innovation of leading firms but to depress it among nonleading firms in several countries (Cusolito et al. 2021, Iacovone 2012).

    Although tariffs on goods are relatively low in East Asia, non-tariff measures in manufacturing and restrictions on services limit competition. For instance, in sectors dominated by state-owned enterprises (SOEs), frontier firm productivity growth is significantly lower than in other sectors.

    Policy reforms that increase exposure to competition can be powerful tools to accelerate productivity growth. For example, liberalisation of services markets following Viet Nam’s WTO accession in 2007 are associated with 5% faster productivity growth of frontier firms in these same services sectors and over 10% in downstream manufacturing firms that use these services (see Figure 2).

    Figure 2 Opening services to competition in Viet Nam increased productivity in these services sectors as well as in downstream manufacturing sectors that use services inputs

    Note: The figure presents within-firms estimates of changes in total factor productivity between 2008 and 2016 and changes in the STRI of the World Bank and World Trade Organization. Coefficients reflect the estimated increase in productivity for a 1 standard deviation decrease in STRI. All coefficients are statistically significant at the 95 percent level. “Frontier firms” are defined as the top 10 percent most-productive firms within an industry, and “laggard firms” are the bottom 10 percent. The main explanatory variable is the change in STRI values in the trade, transport, finance, professionals, and telecommunications sectors between 2016 and 2008 in the “direct own-sector effect,” and the change in the “downstream” STRI for manufacturing sectors in “downstream effect.” The downstream STRI is a sector-specific measure for each two-digit manufacturing sector, calculated by the average STRI of the 5 services sectors, weighted by the corresponding purchasing value from each manufacturing sector. The regression sample in “direct own-sector effect” consists of all enterprises operating in the trade, transport, finance, professionals, and telecommunications sectors, and all manufacturing enterprises in “downstream effect,” in 2008 and 2016. STRI = Services Trade Restrictions Index.

    2 Firms need stronger capabilities

    Productivity growth and adoption of sophisticated technologies require a broad range of skills and high-quality digital infrastructure. Yet basic skills remain limited. In several East Asian economies, more than half of 10-year-olds are unable to read an age-appropriate passage. Management quality remains a challenge, with the best-managed firms in the region especially far behind the best-managed firms globally. Meanwhile, access to high-speed fibre broadband – critical for cloud-based tools and AI – is uneven across and within countries.

    Improving skills is key.  Reforms are needed to fix the foundation of basic skills on which more-advanced skills can be built. Equipping workers with the skills that complement new technologies and enhancing the abilities of managers are crucial to accelerating productivity (Arias et al. 2025).  Increased investment in new technologies is correlated with higher firm productivity in Viet Nam, but only for firms with a sufficiently skilled workforce (see Figure 3). 

    Figure 3 Productivity gains from technology adoption accrue to firms with more-skilled workers

    Note: The figure presents results from an estimation of within-firm changes in TFP on changes in the (log) value of a firm’s primary production technology per worker, interacted with a skills quartile dummy. Based on 2010–18 firm-level data for Viet Nam. Skills are measured in the initial period and reflect the share of a firm’s workers with a university degree, and quartiles are calculated within a two-digit industry. Error bars denote 90 percent confidence intervals; hence, the coefficients on the bottom skill quartile are not significantly different from zero. TFP = total factor productivity.

    3 The case for coordinated reforms

    Boosting productivity at the frontier requires a package of mutually reinforcing reforms: enhancing competition by liberalising services and reducing non-tariff barriers; building skills, from foundational literacy to advanced technical and managerial capabilities; and expanding digital infrastructure, thus ensuring access to high-speed internet and cloud services.

    Synchronizing reforms can help exploit the synergies between enhanced human capital, infrastructure, and competition.  For example, both openness to foreign competition and access to fibre broadband for firms in the Philippines increased technology adoption, but their combined impact was more than double. Similarly, widening access to higher education in China increased productivity, especially for foreign-owned firms. Also, trade liberalization in Indonesia led to productivity-enhancing increases in foreign direct investment, especially for firms with more-skilled workforces.

    Conclusions

    The relative stagnation of East Asia’s frontier firms is a challenge for long-term growth. In a world of accelerating technological change, maintaining competitiveness requires more than broad access to digital infrastructure. It requires ensuring that the most productive firms can innovate, expand, and adopt cutting-edge technologies. Our findings call for coordinated reforms – in skills, infrastructure, and competition – that can unleash the potential of East Asian firms and ensure they keep pace with the best in the world.

    Authors’ note: The opinions expressed in this column are entirely those of the authors. They do not necessarily represent the views of the International Bank for Reconstruction and Development/World Bank and its affiliated organisations, or those of the Executive Directors of the World Bank or the governments they represent.

    References

    Arias, O, D Fukuzawa, D Le and A Mattoo (2025), “Future jobs: AI, robots, and jobs in developing countries”, VoxEU.org, 30 August.

    Aghion, P, C Antonin, and S Bunel (202a), The Power of Creative Destruction: Economic Upheaval and the Wealth of Nations, Harvard University Press.

    Baldwin, R (2016), The Great Convergence: Information Technology and the New Globalization, Harvard University Press.

    Blanchenay, P, C Criscuolo, and G Berlingieri (2017), “Great Divergences: The growing dispersion of wages and productivity in OECD countries”, VoxEU.org, 15 May.

    Cusolito, A P, A Garcia-Marin, and W F Maloney (2021), “Proximity to the frontier, markups, and the response of innovation to foreign competition”, VoxEU.org, 4 November.

    Criscuolo, C, P Gal, and D Andrews (2017), “The best vs the rest: The global productivity slowdown hides an increasing performance gap across firms”, VoxEU.org, 27 March.

    De Nicola, F, A Mattoo, and J Timmis (2025), Firm Foundations of Growth: Productivity and Technology in East Asia and Pacific, East Asia and Pacific Development Studies, World Bank.

    Iacovone, L (2012), “The Better You Are, The Stronger It Makes You: Evidence on the Asymmetric Impact of Liberalization”, Journal of Development Economics 99(2): 474–85

    Williamson, J G and K O’Rourke (2017), “The spread of modern manufacturing to the poor periphery”, VoxEU.org, 3 April.

    Continue Reading

  • Parker vs Wardley: Fabio Wardley stops Joseph Parker in huge heavyweight upset

    Parker vs Wardley: Fabio Wardley stops Joseph Parker in huge heavyweight upset

    Fabio Wardley pulled off a huge upset to wreck Joseph Parker’s dreams of becoming a two-time world heavyweight champion on Saturday and put himself in position for a shot at undisputed champion Oleksandr Usyk.

    The British fighter is now the number…

    Continue Reading

  • Tax rises could push food prices higher, warn supermarkets

    Tax rises could push food prices higher, warn supermarkets

    [Getty Images]

    The bosses of Britain’s biggest supermarkets have warned food prices could rise even further if higher taxes are imposed on the sector.

    Grocers including Tesco, Asda, Sainsbury’s and Morrisons signed a letter to Chancellor Rachel Reeves ahead of her Budget next month, along with Lidl, Aldi, Iceland, Waitrose and M&S.

    They claimed households would “inevitably feel the impact” of any potential tax increases on the industry, such as higher business rates for supermarkets.

    The Treasury said tackling food price inflation was a “priority” and said it was lowering business rates for “butchers, bakers and other shops”.

    In their letter to the Chancellor, supermarket bosses said if the industry was to face higher taxes, “our ability to deliver value for our customers will become even more challenging and it will be households who inevitably feel the impact”.

    “Given the costs currently falling on the industry, including from the last Budget, high food inflation is likely to persist into 2026,” they warned.

    “This is not something that we would want to see prolonged by any measure in the Budget.”

    Ahead of the chancellor’s Autumn Budget next month, speculation is growing over her tax and spending policies.

    She is widely expected to increase taxes following gloomy economic forecasts and a series of U-turns on cuts to welfare spending, which have made it more difficult for her to meet her self-imposed borrowing rules.

    After announcing tax rises of £40bn in her previous Budget in November, which included a hike in the amount employers are required to pay in National Insurance Contributions, Reeves said she was “not coming back” for more tax rises.

    But economists at the influential Institute for Fiscal Studies (IFS) have calculated a shortfall of £22bn in the public finances and suggested Reeves will “almost certainly” have to raise taxes.

    The think tank cited rising borrowing costs for the government, weaker growth forecasts, and spending commitments made since the spring as reasons for the tight position.

    Many industries in the run-up to the Budget often call on and lobby their views and position to the government, but rising food prices are once again putting pressure on people’s finances.

    The cost of many staples has spiked compared with butter prices up by 19% and milk over 12% along with chocolate and coffee rising 15%, according to the Office for National Statistics.

    Continue Reading